Literature DB >> 21526374

Preoperative risk evaluation of postoperative morbidity in IBD patients--impact of the POSSUM score.

Jan-Hendrik Egberts1, Antje Stroeh, Ibrahim Alkatout, Freya A Goumas, Phillipp A Brand, Clemens Schafmayer, Thomas Becker, Bodo Schniewind.   

Abstract

BACKGROUND: The aim of this study was to assess the morbidity and mortality of patients undergoing surgery for inflammatory bowel disease (IBD) with special focus of the predictive value of the Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (POSSUM) scoring system for preoperative risk adjustment of postoperative morbidity.
METHODS: The operative notes and hospital files of 191 patients with IBD were analyzed. The POSSUM scoring system was used to predict morbidity rates after surgery. The physiological sub-score of the POSSUM score was analyzed with regard to its ability to predict postoperative complications.
RESULTS: The overall complication rate was 27.7%, and the mortality was 0.5%. The morbidity rate predicted by POSSUM was 28.4% and the mortality rate 7.2%. The mean POSSUM-phys sub-score in patients without the major complications (anastomotic leakages, peritonitis, bleeding) was significant lower compared to patients with at least one of these complications (14.7 vs. 18.6; p < 0.001). Regarding the major complications separately, there were significant differences in the POSSUM-phys scores in patients developing a sepsis (14.1 vs. 23.4; p < 0.001) and/or a peritonitis (14.8 vs. 19.2; p = 0.05), whereas patients developing an anastomotic leakage/suture dehiscence or a postoperative bleeding did not differ significantly.
CONCLUSION: POSSUM was an accurate predictor of morbidity in IBD patients and overpredicted mortality. The POSSUM-phys score is a promising instrument for identifying patients at increased risk of developing major postoperative complications after surgery for IBD.

Entities:  

Mesh:

Year:  2011        PMID: 21526374     DOI: 10.1007/s00384-011-1179-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  23 in total

1.  Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates.

Authors:  A J Greenstein; D B Sachar; B S Pasternack; H D Janowitz
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Risk factors for initial surgery in pediatric patients with Crohn's disease.

Authors:  Neera Gupta; Stanley A Cohen; Alan G Bostrom; Barbara S Kirschner; Robert N Baldassano; Harland S Winter; George D Ferry; Terry Smith; Oren Abramson; Benjamin D Gold; Melvin B Heyman
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 3.  Inflammatory bowel disease: clinical aspects and established and evolving therapies.

Authors:  Daniel C Baumgart; William J Sandborn
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

4.  ASA status and age predict adverse events after abdominal surgery.

Authors:  J C Hall; J L Hall
Journal:  J Qual Clin Pract       Date:  1996-06

Review 5.  Factors affecting recurrence after surgery for Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

6.  The long-term outcome of restorative operation in Crohn's disease: influence of location, prognostic factors and surgical guidelines.

Authors:  Y M Trnka; D J Glotzer; E J Kasdon; H Goldman; M L Steer; L D Goldman
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

Review 7.  Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis.

Authors:  Takayuki Yamamoto; Victor W Fazio; Paris P Tekkis
Journal:  Dis Colon Rectum       Date:  2007-11       Impact factor: 4.585

8.  Comparison of individual surgeon's performance. Risk-adjusted analysis with POSSUM scoring system.

Authors:  P M Sagar; M N Hartley; J MacFie; B A Taylor; G P Copeland
Journal:  Dis Colon Rectum       Date:  1996-06       Impact factor: 4.585

9.  Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.

Authors:  Adrian A Indar; Tonia M Young-Fadok; Jacques Heppell; Jonathan E Efron
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

10.  State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

View more
  5 in total

1.  Complications after end-to-end vs. side-to-side anastomosis in ileocecal Crohn's disease--early postoperative results from a randomized controlled multi-center trial (ISRCTN-45665492).

Authors:  Urte Zurbuchen; Anton J Kroesen; Philipp Knebel; Michael-Hans Betzler; Heinz Becker; Hans-Peter Bruch; Norbert Senninger; Stefan Post; Heinz J Buhr; Jörg-Peter Ritz
Journal:  Langenbecks Arch Surg       Date:  2013-03       Impact factor: 3.445

2.  Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis.

Authors:  Bernhard W Renz; Wolfgang E Thasler; Gerhard Preissler; Tobias Heide; Philippe N Khalil; Michael Mikhailov; Karl-Walter Jauch; Martin E Kreis; Markus Rentsch; Axel Kleespies
Journal:  J Gastrointest Surg       Date:  2013-03-09       Impact factor: 3.452

3.  The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Mark S Salem; Amar R Deshpande; Daniel A Sussman
Journal:  Dig Dis Sci       Date:  2013-03-13       Impact factor: 3.199

Review 4.  Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge.

Authors:  C Seifarth; J P Ritz; U Pohlen; A J Kroesen; B Siegmund; B Frericks; H J Buhr
Journal:  Int J Colorectal Dis       Date:  2014-05-04       Impact factor: 2.571

Review 5.  Patient optimization for surgery relating to Crohn's disease.

Authors:  Kamal V Patel; Amir A Darakhshan; Nyree Griffin; Andrew B Williams; Jeremy D Sanderson; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-26       Impact factor: 46.802

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.